Slide 1: Financial Results Quarter Ended June 30, 2014
Financial Results Quarter Ended June 30, 2014
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : Tuesday, August 05, 2014 Time : 05:00 pm IST Primary Number: +91 22 6746 8354 Secondary Number: +91 22 3938 1071 6000 1221 Available in – Ahmedabad, Bengaluru, Chennai, Cochin, Delhi, Gurgaon, Hyderabad, Kolkata, Noida. Accessible from all major carriers except BSNL/MT
Slide 4: Corporate Actions
CORPORATE ACTIONS • Consolidation of Pharmaceutical business under Jubilant Pharma completed • Completed the consolidation of all our Pharmaceutical business under Jubilant Pharma, Singapore with effect from 1st July, 2014. • Financed by US$ 147.5m funding from IFC • IFC funding includes the followi
Slide 5: Q1 FY15 Results Analysis
JUBHANT LIFESCIENCES Q1 FY15 Results Analysis
Slide 6: Key Business Segments – Q1'FY15
Key Business Segments – Q1’FY15 Jubilant Life Sciences Pharmaceuticals Life Science Ingredients (41%) (59%) Generics Active Pharmaceutical Ingredients Advanced Intermediates Solid Dosage Formulations and Specialty Ingredients Specialty Pharmaceuticals (Sterile Products) Radiopharmaceutical
Slide 7: Income Statement – Q1'FY15
Income Statement – Q1’FY15 Particulars Q1'FY14 Q4'FY14 Q1'FY15 YoY Growth QoQ Growth (Rs Crs) (%) Total Income from Operations 1,359 1,562 1,473 8% -6% Total Expenditure 1,121 1,317 1,328 Other Income 6 5 4 EBITDA including Other Income 244 251 150 -39% -40% Depreciation 68 69 73 Finance Cost 65 65
Slide 8: Financial Highlights – Q1'FY15
Financial Highlights – Q1’FY15 • Income from Operations at Rs. 1,473 crs, up 8% YoY • Backed by 5% price increase • International revenues grew 5% YoY at Rs. 1,051 crs; contribute 71% to total sales • Entered Indian branded pharmaceuticals market during the quarter • EBITDA at Rs. 150 crs • EBITDA M
Slide 9: Segmental Revenue Analysis – Q1'FY15
Segmental Revenue Analysis – Q1’FY15 Revenue (Rs. Crs.) Revenue YoY QoQ Segmental Revenue Analysis Q1'FY14 Q4'FY14 Q1'FY15 Mix (%) Growth % Growth % Pharmaceuticals 653 705 604 41% -7% -14% Life Science Ingredients 706 858 869 59% 23% 1% Income from Operations 1,359 1,562 1,473 100% 8% -6% Inter Div
Slide 10: Business Highlights – Q1'FY15
Business Highlights – Q1’FY 15 Generics Active Pharmaceutical Ingredients • 31 commercial APIs, including 19 in North America, 24 in Europe and 26 in ROW • 39 filings globally during the quarter and launched Paroxetine in Japan • Expecting commercialization of some key products such as Telmisartan,
Slide 11: Business Highlights – Q1'FY15
Business Highlights – Q1’FY 15 Specialty Pharmaceuticals (Sterile products) Radiopharmaceuticals • Revenue increase witnessed in key Radiopharmaceuticals products • Executed multi-year supply agreements with key customers • Ruby-Fill expected to be launched in Q4 FY2015, subject to necessary regulat
Slide 12: Business Highlights – Q1'FY15
Business Highlights – Q1’FY 15 India Branded Pharmaceuticals • Made a foray into the Indian Pharmaceuticals Market with a field strength of 200 plus • Launch of a Cardiovascular-Diabetic Division Advanced Intermediates and Specialty Ingredients • Volume growth in Pyridine • Order wins continue to ad
Slide 13: Revenue Analysis – Geography wise – Q1'FY15
Revenue Analysis – Geography wise- Q1’FY15 Geo-wise Revenue (Rs crs) Q1'FY14 Q4'FY14 Q1'FY15 Mix % YoY % ROW 5.9% India 359 403 422 29% 18% China 9.8% International 1,001 1,159 1,051 71% 5% India USA & Canada 522 581 490 33% -6% 28.7% Europe & Japan 273 320 330 22% 21% Europe & Japan China 123 161 1
Slide 14: Operating Expenditure Analysis – Q1'FY15
Operating Expenditure Analysis – Q1’FY15 % of % of YoY QoQ Expenses (Rs Crs) Q1’FY14 % of Sales Q4’FY14 Q1’FY15 Sales Sales Growth % Growth % Material Cost 582 43% 695 44% 719 49% 24% 4% Power & Fuel Cost 92 7% 96 6% 99 7% 8% 3% Employee Cost 256 19% 284 18% 272 18% 6% -4% Other Expenses 192 14% 242
Slide 15: EBITDA Analysis – Q1'FY15
EBITDA Analysis – Q1’FY15 EBITDA (Rs. Crs) Business Segments Q1'FY14 Q4'FY14 Q1'FY15 YoY Growth % QoQ Growth % Pharmaceuticals 150 132 36 -76% -73% Life Science Ingredients 109 131 133 23% 1% Less: Corp Expenses -15 -13 -19 Reported EBITDA 244 251 150 -39% -40% Margins (%) YoY Variance (Bps) QoQ Var
Slide 16: Exceptional Items – Q1'FY15
Exceptional Items – Q1’FY15 Total exceptional items for Q1’FY15 – Rs. (19) crs • Unrealized Mark to Market book gain - Rs. 2 crs mainly on account of • Currency movement of USD, from Rs. 59.91 as on March 31, 2014 to Rs. 60.18 as on June 30, 2014, with respect to Rupee Loan of Rs. 850 crs swapped in
Slide 17: Debt Profile
Debt Profile Particulars 30-Jun-13 31-Mar-14 30-Jun-14 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 281 265 264 Swapped loan in Standalone 202 189 189 Subsidiaries 182 199 253 Total 665 652 706 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 531 480 160 Total 531 480 160 Gross Debt 4,
Slide 18: Outlook
Outlook Robust Outlook going forward • Sales and EBITDA growth in Pharmaceuticals on account of resolution of Warning Letter in Montreal and revenue increase in key Radiopharmaceuticals products • Life Science Ingredients to deliver robust performance on account of higher capacity utilization and be
Slide 19: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1002 Ph: +91-22-6645 1209 E-mail: ravi_agrawal@jubl.com E-mail: siddharth@cdr-india.com Anupam Jain Karl Kolah Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1021 P